|
Jul 3
|
5 Must-Read Analyst Questions From Illumina’s Q1 Earnings Call
|
|
Jun 30
|
Proteomic Biomarker Analytics Market Forecast Report 2025: Proteomics Steps Up Where Genomics Falls Short
|
|
Jun 20
|
FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?
|
|
Jun 20
|
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Brush Off
|
|
Jun 18
|
3 Reasons ILMN is Risky and 1 Stock to Buy Instead
|
|
Jun 17
|
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
|
|
May 30
|
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
|
|
May 30
|
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis
|
|
May 29
|
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
|
|
May 29
|
Illumina widens access to cancer tests with Medicare and new CDx
|
|
May 28
|
Stifel Affirms Buy Rating on Illumina (ILMN) Stock
|
|
May 28
|
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
|
|
May 28
|
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
|
|
Mar 14
|
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
|
|
Mar 11
|
Stocks to Watch Tuesday: Tesla, Southwest, Oracle, Illumina
|
|
Mar 10
|
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
|
|
Mar 10
|
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
|
|
Mar 10
|
Illumina addresses recent developments in China
|
|
Mar 10
|
Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025
|
|
Feb 24
|
Trump’s Early Policy Moves Create New Headaches for This Biotech Heavyweight
|